Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
15.08.2024 15:48:00
|
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.The thing is that all of those treatments are manufactured by just two pharmaceutical companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). Yet despite limited competition at the moment, a number of companies of all sizes are looking to get involved. One of these companies is Switzerland-based Roche Holdings (OTC: RHHBY).Interestingly, Roche has gotten very little coverage when it comes to emerging opportunities in the weight loss space. I think that's going to change very soon.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lillymehr Nachrichten
Analysen zu Eli Lillymehr Analysen
20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
13.02.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Eli Lilly | 713,10 | -0,28% |
|
Novo Nordisk (spons. ADRs) | 60,40 | -1,63% |
|